# Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Source: https://onco.cc/trials/nct03945162/  
OnCo record `nct03945162` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ruvidar® (TLD-1433) bladder infusion and PDT in bladder & urothelial cancer, run by Theralase® Technologies Inc., now recruiting.

## Summary

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients is a phase 2 interventional study registered as NCT03945162 by Theralase® Technologies Inc., with 90 participants planned, started 2019-08-30 and due to reach its primary completion in 2026-12. Interventions recorded: Ruvidar® (TLD-1433) bladder infusion and PDT.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03945162
- Phase: 2
- Setting: A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy ("Study II")
- Sponsor: Theralase® Technologies Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT03945162: https://clinicaltrials.gov/study/NCT03945162

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct03945162.json